Summary background Malaria control programmes need to protect young children, who
bear the brunt of malaria disease and death in Africa. The development of a vaccine is a …

The most likely mechanism to deliver a malaria vaccine in African countries is through the
Expanded Program of Immunization (EPI). So far only SPf66, a multistage synthetic peptide …

The development of a malaria vaccine is a priority for improved and sustained malaria
control. Optimal use of a vaccine in Africa will only be achieved if it can be delivered through …

SPf66 malaria vaccine is a synthetic protein with aminoacid sequences derived from pre-
erythrocytic and asexual blood-stage proteins of Plasmodium falciparum. SPf66 was found …

Effective, safe antimalarial vaccines have proved elusive. The synthetic polypeptide SPf66
vaccine is based on pre-erythrocytic and asexual blood-stage proteins of Plasmodium …

Background Previous efficacy trials of SPf66 malaria vaccine have produced conflicting
results in different populations. We report a randomised double-blind trial of the SPf66 …

Malaria, especially that due to Plasmodium falciparum, is one of the most important parasitic
disease in man. It causes more than 400 million cases per year and between 1 to 3 million …

The SPf66 synthetic vaccine is safe and partly efficacious against Plasmodium falciparum
malaria among children 1–5 years old. The estimated vaccine efficacy [VE] for all clinical …

A pilot safety and immunogenicity trial of the malaria vaccine SPf66 was undertaken in The
Gambia in 1993. One hundred and fifty infants aged 6–11 months were immunized with …

In 1994, 630 Gambian infants were immunized with three doses of the synthetic polypeptide
malaria vaccine SPf66 or with a control vaccine. No significant protection against first or total …